Correspondence 0001493152-24-050406 from AIxCrypto Holdings, Inc. (AIXC)
AIxCrypto Holdings, Inc.
Date: Dec. 17, 2024 · CIK: 0001460702 · Accession: 0001493152-24-050406
AI Filing Summary & Sentiment
Reasoning
Letter
Qualigen Therapeutics, Inc.
Owens Avenue, Suite 300
Carlsbad, California 92008
December 17, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attn: Tylor Howes
Re: Qualigen Therapeutics, Inc.
Registration Statement on Form S-1
File 33-283708
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Qualigen Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to December 19, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Sichenzia Ross Ference Carmel LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We request that we be notified of such effectiveness by a telephone call to Ross D. Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel to the Company, at 646-838-1310 and that such effectiveness also be confirmed in writing.
Very
truly yours,
Qualigen
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Qualigen
Therapeutics, Inc.
5857
Owens Avenue, Suite 300
Carlsbad,
California 92008
December
17, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attn:
Tylor Howes
Re:
Qualigen
Therapeutics, Inc.
Registration
Statement on Form S-1
File
33-283708
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Qualigen Therapeutics, Inc. (the “Company”)
hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”)
be accelerated to December 19, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel,
Sichenzia Ross Ference Carmel LLP, request by telephone that such Registration Statement be declared effective at some other time. In
making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
We
request that we be notified of such effectiveness by a telephone call to Ross D. Carmel, Esq. of Sichenzia Ross Ference Carmel LLP, counsel
to the Company, at 646-838-1310 and that such effectiveness also be confirmed in writing.
Very
truly yours,
Qualigen
Therapeutics, Inc.
By:
/s/
Kevin Richardson II
Kevin
Richardson II
Interim
Chief Executive Officer